obewon/iStock via Getty Images
- The commercial-stage biotech Amarin Corporation (NASDAQ:AMRN) dropped for the third straight session on Thursday after Stat News raised concerns over the effectiveness of its heart disease therapy Vascepa.
- Following a new analysis, the report said that multiple experts called for a clinical trial to address the questions over Vascepa. Some had even urged the U.S. Food and Drug Administration (FDA) to reconsider its approval, Stat News reported.
- Early this month, Amarin (AMRN) said it expected to receive pricing decisions for Vascepa, known as Vazkepa in Europe, in up to eight countries. The company expects to launch the product in up to six European countries this year.
- Vascepa, a medicine derived from fish oil, was launched in the U.S. in January 2020 after the FDA greenlighted it for certain adult patients with hypertriglyceridemia as an adjunct therapy to diet.